Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Relapsed CML Post-SCT
NCT00895297Phase 2Terminated
- Start
- Feb 2010
- Primary completion
- Oct 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML). Started Feb 2010; status: terminated.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00895297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895297.